Crossmark

Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial

Crossref DOI link: https://doi.org/10.1186/s12882-018-0973-7

Published Online: 2018-07-11

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sedhain, Arun http://orcid.org/0000-0003-2590-9096
Hada, Rajani

Agrawal, Rajendra K.

Bhattarai, Gandhi R.

Baral, Anil
License Information

Text and Data Mining valid from 2018-07-11
More Information

Article History

Received: 12 July 2017

Accepted: 27 June 2018

First Online: 11 July 2018

Ethics approval and consent to participate

: Ethical approval was obtained from the Institutional Review Board of National Academy of Medical Sciences (NAMS), Kathmandu, Nepal. Patients gave informed written consent to participate in the study. Written informed consent was also obtained from the parents of the participants below 18 years of age.

: Not applicable.

: AS is employed by Chitwan Medical College and does not have financial benefits in participating in the study.RH, RKA and AB are employed by the Government of Nepal and currently posted at National Academy of Medical Sciences and have not received any financial benefits for getting involved in the study.GRB is employed by UnitedHealth Group and also owns company stocks. No financial benefits are received in participating in this study.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.